<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258527</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI375A101</org_study_id>
    <nct_id>NCT04258527</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations</brief_title>
  <official_title>A Phase 1, Open-Label, Pharmacokinetic(PK), Pharmacodynamics(PD) and Safety Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study to investigate the characteristics of PK, PD and safety in subjects&#xD;
      with advanced malignancies with FGF/FGFR alterations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2020</start_date>
  <completion_date type="Actual">March 8, 2021</completion_date>
  <primary_completion_date type="Actual">July 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) during the dosing interval and Cmin of Pemigatinib as monotherapy</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of Pemigatinib as monotherapy</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the single-dose plasma concentration-time curve (AUC0-t) of Pemigatinib as monotherapy</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of pemigatinib as monotherapy as assessed by the frequency, duration, and severity of adverse events</measure>
    <time_frame>From screening through 30-35 days after end of treatment, up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Patients with advanced malignancies with FGF/FGFR alterations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemigatinib</intervention_name>
    <description>Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.</description>
    <arm_group_label>Patients with advanced malignancies with FGF/FGFR alterations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, aged 18 or older.&#xD;
&#xD;
          2. Histologically or cytologically confirmed malignancy which was considered to be&#xD;
             surgically unresectable advanced, relapse or metastatic .&#xD;
&#xD;
          3. Radiographically measurable disease per RECIST v 1.1&#xD;
&#xD;
          4. Documentation of FGF/FGFR alteration..&#xD;
&#xD;
          5. Documented disease progression after standard therapy ,or no standard therapy&#xD;
             available.&#xD;
&#xD;
          6. ECOG performance status of 0~1.&#xD;
&#xD;
          7. Life expectancy â‰¥12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior receipt of a selective FGFR inhibitor.&#xD;
&#xD;
          2. History of calcium and phosphate hemostasis disorder or systemic mineral imbalance&#xD;
             with ectopic calcification of softy tissues ( exception: skin, kidney, tendons or&#xD;
             vessels due to injury, disease, and aging, in the absence of systemic mineral&#xD;
             imbalance).&#xD;
&#xD;
          3. Currently evidence of clinically significant corneal or retinal disorder confirmed by&#xD;
             ophthalmologic examination.&#xD;
&#xD;
          4. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives,&#xD;
             whichever is shorter, before the first dose of study drug. Topical ketoconazole will&#xD;
             be allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

